Xencor, Inc. (NASDAQ:XNCR) has been given a $36.00 target price by analysts at Canaccord Genuity in a research note issued on Monday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Canaccord Genuity’s target price would suggest a potential upside of 75.78% from the stock’s current price.

Other research analysts have also recently issued research reports about the company. ValuEngine raised Xencor from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. BidaskClub cut Xencor from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. Finally, Zacks Investment Research cut Xencor from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $28.00.

Xencor (XNCR) traded down 3.80% during midday trading on Monday, hitting $20.48. The company had a trading volume of 137,198 shares. The company’s market capitalization is $961.04 million. Xencor has a 52 week low of $18.45 and a 52 week high of $29.38. The stock has a 50 day moving average price of $22.80 and a 200 day moving average price of $22.43.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.10. Xencor had a negative return on equity of 13.79% and a negative net margin of 121.04%. The company had revenue of $13.34 million for the quarter, compared to analysts’ expectations of $8.15 million. Equities analysts forecast that Xencor will post ($1.17) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/23/xencor-inc-xncr-given-a-36-00-price-target-at-canaccord-genuity.html.

In other Xencor news, major shareholder John S. Stafford III acquired 43,500 shares of the stock in a transaction dated Friday, August 18th. The stock was purchased at an average price of $19.93 per share, with a total value of $866,955.00. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder John S. Stafford III acquired 79,035 shares of the stock in a transaction dated Thursday, August 17th. The stock was acquired at an average cost of $20.47 per share, with a total value of $1,617,846.45. The disclosure for this purchase can be found here. Insiders bought a total of 215,551 shares of company stock valued at $4,386,916 in the last three months. Insiders own 4.03% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. Alps Advisors Inc. boosted its position in shares of Xencor by 0.3% in the 2nd quarter. Alps Advisors Inc. now owns 20,102 shares of the biopharmaceutical company’s stock worth $424,000 after purchasing an additional 52 shares in the last quarter. Falcon Point Capital LLC boosted its position in shares of Xencor by 0.5% in the 2nd quarter. Falcon Point Capital LLC now owns 29,082 shares of the biopharmaceutical company’s stock worth $614,000 after purchasing an additional 156 shares in the last quarter. Parametric Portfolio Associates LLC raised its stake in Xencor by 0.6% in the 1st quarter. Parametric Portfolio Associates LLC now owns 36,253 shares of the biopharmaceutical company’s stock worth $867,000 after acquiring an additional 209 shares during the last quarter. Legal & General Group Plc raised its stake in Xencor by 4.5% in the 2nd quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock worth $189,000 after acquiring an additional 385 shares during the last quarter. Finally, Cornerstone Capital Management Holdings LLC. raised its stake in Xencor by 2.3% in the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 23,321 shares of the biopharmaceutical company’s stock worth $492,000 after acquiring an additional 521 shares during the last quarter. 76.92% of the stock is owned by hedge funds and other institutional investors.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Analyst Recommendations for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.